Literature DB >> 3497913

Antibiotics in Yersinia enterocolitica infections.

J A Hoogkamp-Korstanje.   

Abstract

A prospective study was undertaken to evaluate the incidence, course, effects of treatment and outcome of patients with Yersinia enterocolitica infections. A total of 189 patients were followed: 62.5% had enteric forms of illness, 20.6% extramesenteric forms, 23.2% arthritis and erythema nodosum. Lymphadenopathy with high fever and weight loss, a septic syndrome and hepatitis were predominant manifestations of the extramesenteric form. Ten per cent of the isolates (135) were susceptible to amoxycillin (4 mg/l), 38% to cephradine (8 mg/l), 82% to doxycycline (4 mg/l), 83% to chloramphenicol (4 mg/l), 85% to trimethoprim (1 mg/l), 87% to cefuroxime (8 mg/l), 92% to piperacillin (16 mg/l), 99% to gentamicin (1 mg/l) and 100% to cefotaxime (4 mg/l), pefloxacin (0.12 mg/l), ofloxacin (0.06 mg/l) and ciprofloxacin (0.016 mg/l). The majority of the patients with enteritis recovered without antibiotic therapy. The duration of enteritis was not significantly influenced by antibiotic treatment. Eighty five patients, 46 with enteric and 39 with extramesenteric forms were treated. The clinical response to co-trimoxazole was 71%, and to doxycycline 75%. Cefuroxime, ceftazidime, cefoperazone, piperacillin and gentamicin failed in seven of eight courses. Three patients treated with ciprofloxacin responded well. The role of quinolones in yersiniosis needs further attention.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497913     DOI: 10.1093/jac/20.1.123

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Relapsing yersinia infection.

Authors:  R C Read; R E Barry
Journal:  BMJ       Date:  1990-06-30

2.  A fatal case of Yersinia enterocolitica septicemia associated with mycotic aortic aneurysm.

Authors:  J D Knudsen; M Arpi; K T Jensen
Journal:  Infection       Date:  1993 Sep-Oct       Impact factor: 3.553

3.  Endocarditis due to Yersinia enterocolitica.

Authors:  E Bonnet; M Archambaud; A Sommabere; C Suc; Z Elias; M Gallinier; P Massabuau; J P Bounhoure; P Massip
Journal:  Infection       Date:  1998 Sep-Oct       Impact factor: 3.553

4.  Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis.

Authors:  T Yli-Kerttula; R Luukkainen; U Yli-Kerttula; T Möttönen; M Hakola; M Korpela; M Sanila; J Parviainen; J Uksila; R Vainionpää; A Toivanen
Journal:  Ann Rheum Dis       Date:  2000-07       Impact factor: 19.103

5.  Influence of antibiotics on IgA and IgG response and persistence of Yersinia enterocolitica in patients with Yersinia-associated spondylarthropathy.

Authors:  J A Hoogkamp-Korstanje; J de Koning; J Heesemann; J J Festen; P M Houtman; P L van Oyen
Journal:  Infection       Date:  1992 Mar-Apr       Impact factor: 3.553

Review 6.  Yersinia enterocolitica: the charisma continues.

Authors:  E J Bottone
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

7.  Lubeluzole: from anti-ischemic drug to preclinical antidiarrheal studies.

Authors:  Maria Maddalena Cavalluzzi; Roberta Budriesi; Maria Antonietta De Salvia; Laura Quintieri; Monica Piarulli; Gualtiero Milani; Roberta Gualdani; Matteo Micucci; Ivan Corazza; Antonio Rosato; Maurizio Viale; Leonardo Caputo; Carlo Franchini; Giovanni Lentini
Journal:  Pharmacol Rep       Date:  2020-10-19       Impact factor: 3.024

8.  Clinical features of patients with novel Yersinia species.

Authors:  Conor G Loftus; Gavin C Harewood; Franklin R Cockerill; Joseph A Murray
Journal:  Dig Dis Sci       Date:  2002-12       Impact factor: 3.199

9.  Persistence of Yersinia enterocolitica in man.

Authors:  J A Hoogkamp-Korstanje; J de Koning; J Heesemann
Journal:  Infection       Date:  1988 Mar-Apr       Impact factor: 3.553

10.  Antimicrobial susceptibility of pathogenic Yersinia enterocolitica isolated in Canada from 1972 to 1990.

Authors:  M A Preston; S Brown; A A Borczyk; G Riley; C Krishnan
Journal:  Antimicrob Agents Chemother       Date:  1994-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.